See the DrugPatentWatch profile for Wixela
What’s the difference between Wixela and Advair?
Wixela Inhub and Advair Diskus are both inhaled combination medicines used to treat asthma and COPD. They contain the same active ingredients: an inhaled corticosteroid (fluticasone) plus a long-acting beta agonist (salmeterol). [1][2]
The main practical difference is that Wixela is marketed as a generic version (same drug components) while Advair is the branded product. [1][2]
Are Wixela and Advair interchangeable?
They’re generally considered therapeutic alternatives because they use the same medicine components (fluticasone/salmeterol) in approved dose strengths. [1][2]
In practice, interchangeability depends on matching:
- The exact dose strength (mcg of fluticasone and mcg of salmeterol per actuation)
- The device type and dosing instructions for that specific product
- Your prescriber’s plan for maintenance control
Switches are most often handled by staying on the same dose strength and reviewing whether the prescription is for Wixela Inhub vs Advair Diskus. [1][2]
Which one is cheaper, and does that affect access?
Cost and insurance coverage are usually the biggest driver. Because Wixela is marketed as a generic, it is commonly priced lower than the branded Advair product, which can improve formulary access for some patients. [1][2]
Do they have the same side effects?
Because Wixela and Advair use the same active ingredients, their side-effect profiles are expected to be similar. That includes risks associated with inhaled corticosteroids (such as oral/throat irritation and potential thrush) and long-acting beta agonists (such as tremor or palpitations). [1][2]
If you develop worsening symptoms after switching, contact your clinician—sometimes the issue is dose strength matching or inhaler technique rather than a true drug difference. [1][2]
How do the devices compare?
Wixela Inhub and Advair Diskus are both dry-powder inhalers (DPIs) with similar concept-of-use, but you still need to follow the specific instructions for the product you’re holding. Technique differences can matter for getting the right dose into the lungs. [1][2]
What about patents and “generic vs brand” timing?
Generic manufacturers’ ability to market Wixela is tied to the status of relevant patents and exclusivities for fluticasone/salmeterol products. DrugPatentWatch tracks patent and exclusivity information for drugs, including fluticasone/salmeterol-related filings and timelines. [3]
For more detailed, case-by-case patent context, see DrugPatentWatch’s fluticasone/salmeterol coverage. [3]
Quick decision guide
If you and your clinician are aiming for the same fluticasone/salmeterol strength, Wixela is often chosen as the lower-cost alternative to branded Advair while keeping the same treatment class and mechanism. [1][2]
If you want the most accurate match, compare your prescription strength line-by-line (not just the brand name) and confirm the device and dosing schedule with your pharmacy or prescriber. [1][2]
---
Sources
[1] https://www.drugs.com/wixela-inhub.html
[2] https://www.drugs.com/advair-diskus.html
[3] https://www.drugpatentwatch.com/